The ruling is a definitive loss but financially trivial for AstraZeneca. No material stock impact expected given the small dollar exposure and consistency with prior court decisions. Monitor for any appeal (unlikely given dismissal with prejudice and weak legal merits). The broader 340B contract pharmacy landscape remains unchanged.
Price Chart
Executive Summary
AstraZeneca's lawsuit challenging Colorado's 340B contract pharmacy protection law (S.B. 71) was dismissed with prejudice. The court rejected all constitutional claims (preemption, patent, Contracts Clause, Takings Clause), finding the law does not conflict with federal 340B requirements and that AstraZeneca's voluntary participation in 340B forecloses its takings argument. The ruling is consistent with a nationwide pattern of similar losses for drug manufacturers.
Court Ruling Details
Key Facts
- AstraZeneca's constitutional challenge to Colorado's S.B. 71 (340B contract pharmacy protection) dismissed with prejudice on all claims
- Court found standing but rejected preemption, patent, Contracts Clause, and Takings Clause arguments
- AstraZeneca estimated $600,000/month loss from complying with S.B. 71's unlimited contract pharmacy requirement
- Ruling aligns with multiple other federal courts that have rejected similar manufacturer challenges to state 340B laws
- No damages awarded, no injunction issued; case closed
Financial Impact
AstraZeneca estimated $600,000/month in additional costs (~$7.2M annually), which is immaterial relative to $251.4B market cap (0.003%)
Risk Factors
- No material financial risk identified; the $600k/month estimate is de minimis for a $251B market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-cb9aa174bf-AZN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.98 (−3.01%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.98 (+4.15%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.98 (−1.91%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.98 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.98 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.98 (−3.38%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.98 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.98 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.98 (−3.38%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.98 (+3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access